Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.

Serum & Biocon Biologics agree to restructure equity investment

Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR

Olympus announces exclusive U.S. co-marketing agreement with Bracco Diagnostics

The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets

Rajiv Gupta to retire as chairman of Avantor

Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader